ULIXERTINIB + Ruxolitinib for primary myelofibrosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 7 Jan 2025: Trial started, NCT06773195
  2. 14 Jan 2025: Trial registered, NCT06773195

The trials

NCT06773195: A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

State
Under way
Phase
Phase 1 and Phase 2
People
37 planned
Started
7 Jan 2025
Primary completion
Jan 2028
Arms
JAK/MEK inhibition with Ruxolitinib and Ulixertinib
Results
None posted
  1. 7 Jan 2025: Trial started
  2. 14 Jan 2025: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.